ALK and non-small cell lung carcinoma: A total of 1382 patients with completely resected NSCLC with or without EGFR mutations or ALK rearrangements (stage IIA–IIIA, IIIB with N2 disease only, AJCC 8th TNM stage) were enrolled in this trial (54), which began in March 2018.